Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Merus N.V.
  6. News
  7. Summary
    MRUS   NL0011606264

MERUS N.V.

(MRUS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Merus N : Earnings Flash (MRUS) MERUS N.V. Reports Q2 Revenue $12.4M

08/05/2021 | 05:02pm EDT


© MT Newswires 2021
All news about MERUS N.V.
10/15Top Premarket Gainers
MT
10/08MERUS N : SVB Leerink Adjusts Merus' Price Target to $45 from $33, Keeps Outperform Rating
MT
10/07MERUS N : Roth Capital Adjusts Merus N.V Price Target to $40 From $32, Maintains Buy Ratin..
MT
10/07MERUS N : Releases Data on MCLA-158, Zeno Cancer Treatments; Shares Up 29%
MT
10/07MERUS N : Presents Early Clinical Data on MCLA-158 and Preclinical Data on Zenocutuzumab a..
AQ
10/07Merus N.V. Presents Early Clinical Data on MCLA-158 and Preclinical Data on Zenocutuzum..
CI
09/30MERUS N : Announces Poster Presentations on Zenocutuzumab and MCLA-158 at the AACR-NCI-EOR..
AQ
09/07Merus to Participate in Upcoming Investor Conferences
GL
08/05MERUS N : Earnings Flash (MRUS) MERUS N.V. Reports Q2 Revenue $12.4M
MT
08/05MERUS N : Announces Financial Results for the Second Quarter and Provides Business Update
AQ
More news
Analyst Recommendations on MERUS N.V.
More recommendations
Financials (USD)
Sales 2021 44,7 M - -
Net income 2021 -89,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -11,5x
Yield 2021 -
Capitalization 1 094 M 1 094 M -
Capi. / Sales 2021 24,5x
Capi. / Sales 2022 29,0x
Nbr of Employees 117
Free-Float 92,1%
Chart MERUS N.V.
Duration : Period :
Merus N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERUS N.V.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 28,43 $
Average target price 34,67 $
Spread / Average Target 21,9%
EPS Revisions
Managers and Directors
Sven Ante Lundberg President, CEO, CFO & Non-Executive Director
Anand Mehra Chairman
John de Kruif Chief Technology Officer & Senior Vice President
Andrew Joe Chief Medical Officer
Mark T. Iwicki Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
MERUS N.V.62.18%1 094
GILEAD SCIENCES, INC.14.83%83 880
WUXI APPTEC CO., LTD.29.16%66 875
BIONTECH SE222.44%63 484
REGENERON PHARMACEUTICALS14.28%57 402
VERTEX PHARMACEUTICALS-21.55%48 101